Treat-and-Extend Regimen for Diabetic Macular Edema: Real-World Outcomes and Predictive Factors for Treatment Interval Extension
Purpose To evaluate the real-world effectiveness of a TReat and EXtend (TREX) regimen with anti-vascular endothelial growth factor (anti-VEGF) agents in diabetic macular edema (DME) and identify predictors of treatment interval extension.Methods This retrospective single-center study included treatment-naive DME eyes receiving three loading doses of intravitreal bevacizumab followed by TREX treatment with ranibizumab or aflibercept. Best corrected visual acuity (BCVA), central macular thickness, injection numbers, and maximum treatment interval (Tremax) were analyzed over 48 months. Optical coherence tomography biomarkers were evaluated as predictors of Tremax.Results A total of 224 eyes were included. Mean BCVA gains were 10.9 ± 21.1, 11.17 ± 20.64, 14.08 ± 21.40, and 17.12 ± 23.48 ETDRS letters at months 12, 24, 36, and 48, respectively. A Tremax ≥12 weeks was achieved in 57.1% of eyes. Eyes with Tremax <12 weeks had worse baseline BCVA (0.73 ± 0.60 vs. 0.57 ± 0.61 logMAR; p = .005), a higher prevalence of hyperreflective dots (HRD) (52.2% vs. 25.0%; p = .001), and more subfoveal hard exudates (37.0% vs. 20.8%; p = .015). One case each of endophthalmitis and vitreous hemorrhage occurred.Conclusions In this real-world cohort, TREX with anti-VEGF agents was associated with visual and anatomical improvement over up to 48 months. Worse baseline BCVA, hyperreflective dots, and subfoveal hard exudates were associated with shorter Tremax (<12 weeks).
Authors
- Nihat Sayın (ORCID: https://orcid.org/0000-0002-1442-9743)
- Mediha Dilek Ozer
- Mehmet Erdoğan (ORCID: https://orcid.org/0000-0002-2556-7383)
- Sadık Etka Bayramoğlu (ORCID: https://orcid.org/0000-0002-9502-4368)
- İbrahim Koçak (ORCID: https://orcid.org/0000-0003-4683-8346)
- Zeynep Yılmazabdurrahmanoğlu (ORCID: https://orcid.org/0000-0002-6075-8513)
- Sehmus Akpinar (ORCID: https://orcid.org/0000-0002-9361-134X)
- Gulhumar Artis (ORCID: https://orcid.org/0000-0002-5850-6659)
- Mehmet Ozkaya (ORCID: https://orcid.org/0000-0002-8539-1703)
Institutions
- Sivas State Hospital (TR)
- Sağlık Bilimleri Üniversitesi (TR)
- İstanbul Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi (TR)
Publication Details
- Journal
- Seminars in Ophthalmology
- Published
- 2026-11-21
- DOI
- https://doi.org/10.1080/08820538.2026.2766552
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00